View Older Stories View More Recent Stories

Apr 25, 2019 05:24PM Merck (MRK) Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA Met Primary Endpoint, Was not Found to be Superior for OS
Apr 25, 2019 05:19PM Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric
Apr 25, 2019 08:00AM Merck and Viola Davis to Debut A Touch of Sugar During Tribeca Film Festival®
Apr 22, 2019 06:46AM Merck (MRK) Reports FDA Approval of KEYTRUDA (pembrolizumab) in Combination With Inlyta®= (axitinib)
Apr 22, 2019 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 13, 2019 07:00AM Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCM
Apr 11, 2019 05:45PM Merck (MRK) Announces FDA Approval of Expanded Monotherapy Label for its KEYTRUDA
Apr 11, 2019 05:45PM FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)
Apr 10, 2019 06:46AM AstraZeneca (AZN) and Merck's (MRK) LYNPARZA Approved in EU for Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
Apr 10, 2019 06:45AM LYNPARZA® (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
Apr 4, 2019 07:08AM Myriad Genetics (MYGN), AstraZeneca (AZN) and Merck (MRK) Expand Companion Diagnostic Partnership
Apr 2, 2019 06:46AM Merck (MRK) Completes Tender Offer to Acquire Immune Design (IMDZ)
Apr 2, 2019 06:45AM Merck Completes Tender Offer to Acquire Immune Design
Apr 2, 2019 06:30AM Merck to Hold First-Quarter 2019 Sales and Earnings Conference Call on April 30
Apr 1, 2019 04:45PM Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals
Apr 1, 2019 08:34AM Merck (MRK) Reports Data for KEYTRUDA (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR 2019
Apr 1, 2019 08:30AM Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019
Apr 1, 2019 06:55AM Merck's (MRK) KEYTRUDA Approved in China for First-Line Treatment of Metastatic Nonsquamous NSCLC in Combination with Chemotherapy
Apr 1, 2019 06:55AM Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
Apr 1, 2019 06:34AM AstraZeneca (AZN) and Merck (MRK) Announce Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
Apr 1, 2019 06:30AM Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
Mar 20, 2019 06:31AM Merck (MRK), NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration
Mar 20, 2019 06:30AM Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022
Mar 20, 2019 05:30AM MilliporeSigma Opens First M Lab™ Collaboration Center in Europe
Mar 19, 2019 06:30AM MilliporeSigma to Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in China
Mar 14, 2019 06:46AM Merck (MRK) Says EC Approved its KEYTRUDA in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous NSCLC
Mar 14, 2019 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Mar 5, 2019 06:45AM Merck Begins Tender Offer to Acquire Immune Design
Mar 4, 2019 08:00AM MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology
Mar 4, 2019 06:46AM Merck (MRK) Announces EMA Adopts Positive Opinion for its KEYTRUDA for Six-Week Dosing Schedule Across All Current Monotherapy Indications
Mar 4, 2019 06:45AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications
Mar 1, 2019 08:47AM Merck (MRK) Announces LYNPARZA Received Positive EU CHMP Opinion For Use in Germline BRCA-Mutated HER2-
Mar 1, 2019 08:45AM LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use in Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
Feb 26, 2019 06:56AM Merck (MRK), AstraZeneca (AZN) Say LYNPARZA Reduced Risk of Disease Progression or Death as First-Line Maintenance Treatment in gBRCAm
Feb 26, 2019 06:55AM LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer
Feb 21, 2019 06:45AM Merck (MRK) to Acquire Immune Design (IMDZ) for $5.85/Share
Feb 21, 2019 06:45AM Merck to Acquire Immune Design
Feb 20, 2019 06:46AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA Monotherapy for Third-Line Treatment of Patients with Advanced SCLC
Feb 20, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer
Feb 19, 2019 04:59PM Merck (MRK) Reports Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
Feb 19, 2019 04:10PM Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
Feb 19, 2019 08:00AM MilliporeSigma Receives First U.S. Patent for Improved CRISPR Genome-Editing Method
Feb 19, 2019 06:46AM Merck (MRK) Says FDA Approved KEYTRUDA for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
Feb 19, 2019 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
Feb 19, 2019 05:54AM Merck (MRK) Reports Pivotal Phase III Data for BAVENCIO (avelumab) Plus INLYTA (axitinib) in Advanced RCC Published in New England Journal of Medicine (Earlier)
Feb 16, 2019 05:14PM Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Feb 16, 2019 05:00PM KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)
Feb 15, 2019 06:46AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA in Combination with Inlyta as First-Line Treatment for Advanced RCC
Feb 15, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cel
Feb 14, 2019 06:50AM Merck (MRK) Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
View More Recent Stories View Older Stories